A Two-Cohort, Open-Label, Multicenter Study of Trastuzumab Emtansine (T-DM1) in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients Who Have Received Prior Anti-HER2 and Chemotherapy-Based Treatment
A Two-Cohort, Open-Label, Multicenter Study of Trastuzumab Emtansine (T-DM1) in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients Who Have Received Prior Anti-HER2 and Chemotherapy-Based Treatment
This two-cohort, open-label, multicenter study will assess the safety, efficacy and tolerability of trastuzumab emtansine in participants with HER2-positive locally advanced breast cancer (LABC) or metastatic breast cancer (mBC) who have received prior anti-HER2 and chemotherapy-based treatment. Participants in Cohort 1 will be drawn from the general participant population; Cohort 2 will include only Asian participants.
Inclusion Criteria:
Exclusion Criteria:
North Sydney, New South Wales 2059, Australia
South Brisbane, Queensland 4101, Australia
Vienna, 1090, Austria
Vienna, 1090, Austria
Vancouver, British Columbia V5Z 4E6, Canada
Newmarket, Ontario L3Y 2P9, Canada
Bottrop, 46236, Germany
München, 81377, Germany
Wiesbaden, 65199, Germany
Crete, 711 10, Greece
Budapest, H-1077, Hungary
Piacenza, Emilia-Romagna 29100, Italy
Rome, Lazio 00161, Italy
Genoa, Liguria 16132, Italy
Sesto San Giovanni (MI), Lombardy 20099, Italy
Candiolo, Piedmont 10060, Italy
Turin, Piedmont 10126, Italy
Perugia, Umbria 06156, Italy
D.F., 14050, Mexico
DF, 04110, Mexico
Sittard-Geleen, 6162 BG, Netherlands
Brzozów, 36-200, Poland
Otwock, 05-400, Poland
Seoul, 03080, South Korea
Las Palmas de Gran Canaria, LAS Palmas 35016, Spain
Las Palmas de Gran Canaria, LAS Palmas 35020, Spain
Oviedo, Principality of Asturias 33011, Spain
A Coruña, 15006, Spain
Jaén, 23007, Spain
Madrid, 28050, Spain
Chiang Mai, 50200, Thailand
Istanbul, 34865, Turkey (Türkiye)